GoodRx Holdings, Inc. (GDRX) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
GDRX Revenue Growth
Revenue Breakdown (FY 2024)
GDRX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
GDRX Revenue Analysis (2018–2025)
As of May 8, 2026, GoodRx Holdings, Inc. (GDRX) generated trailing twelve-month (TTM) revenue of $787.9 million, reflecting slight decline in growth of -4.4% year-over-year. The most recent quarter (Q1 2026) recorded $194.0 million in revenue, down 0.4% sequentially.
Looking at the longer-term picture, GDRX's 5-year compound annual growth rate (CAGR) stands at +7.7%, indicating steady revenue expansion. The company achieved its highest annual revenue of $796.9 million in 2025, representing a new all-time high.
Revenue diversification analysis shows GDRX's business is primarily driven by Prescription Transactions Revenue (84%), Subscription Revenue (13%), and Other Revenue (3%). With over half of revenue concentrated in Prescription Transactions Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including HIMS (+59.0% YoY), TDOC (-1.5% YoY), and OPRX (+18.8% YoY), GDRX has underperformed the peer group in terms of revenue growth. Compare GDRX vs HIMS →
GDRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GDRXCurrent | $788M | -4.4% | +7.7% | 13.4% | |
 HIMS | $2.3B | +59.0% | +73.6% | 5.2% | |
 TDOC | $2.5B | -1.5% | +18.3% | -10.4% | |
 OPRX | $109M | +18.8% | +20.4% | 10.7% | |
 DOCS | $570M | +15.9% | +37.4% | 39.9% |
GDRX Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $796.9M | +0.6% | $654.1M | 82.1% | $107.0M | 13.4% |
| 2024 | $792.3M | +5.6% | $744.1M | 93.9% | $65.8M | 8.3% |
| 2023 | $750.3M | -2.1% | $683.3M | 91.1% | $-27,007,000 | -3.6% |
| 2022 | $766.6M | +2.8% | $701.5M | 91.5% | $1.7M | 0.2% |
| 2021 | $745.4M | +35.4% | $698.7M | 93.7% | $13.4M | 1.8% |
| 2020 | $550.7M | +41.9% | $521.1M | 94.6% | $-275,719,000 | -50.1% |
| 2019 | $388.2M | +55.6% | $374.2M | 96.4% | $139.7M | 36.0% |
| 2018 | $249.5M | - | $243.5M | 97.6% | $77.3M | 31.0% |
See GDRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GDRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GDRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGDRX — Frequently Asked Questions
Quick answers to the most common questions about buying GDRX stock.
Is GDRX's revenue growth accelerating or slowing?
GDRX revenue growth slowed to -4.4%, below the 5-year CAGR of +7.7%. TTM revenue is $788M. The deceleration marks a shift from historical growth rates.
What is GDRX's long-term revenue growth rate?
GoodRx Holdings, Inc.'s 5-year revenue CAGR of +7.7% reflects the variable expansion pattern. Current YoY growth of -4.4% is near this long-term average.
How is GDRX's revenue distributed by segment?
GDRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.